Group bulletin
The CCTG Central Office will be closed on Monday, February 18, 2019 for Family Day. Regular business hours will resume on Tuesday, February 19, 2019 at 8:30 am EST.
February 06, 2019
 CCTG is pleased to announce that the CRC7 has met its accrual goal of 1180 patients and has been closed to accrual. CCTG CRC.7 (N1048) trial: A Phase II/III Trial of Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision (PROSPECT) Read More |
Save the Date - 2019 Annual Spring Meeting is comingPublished: February 06, 2019Category: Group updates  The 2019 CCTG Annual Spring Meeting of Participants will be here before you know it! Make sure that you save the date: May 3 - 5, Chelsea Hotel, Toronto.
The Canadian Cancer Trials Group Annual Spring Meeting of Participants represents a major gathering of the Canadian oncology community where trials that cover the spectrum of cancer treatment are designed and reviewed. Traditionally, the meeting includes discussions of trials that are in development, under conduct or have results to be shared.
|
 The IND234 clinical trial, conducted by the Canadian Cancer Trials Group (CCTG), uses liquid biopsy technology to screen for genomic markers in prostate cancer patients. After the liquid biopsy analysis, patients with specific DNA markers are assigned to one of five new therapies targeted at their unique form of prostate cancer. Researchers want to see if the markers identified in the screening process can help predict which patients will be helped the most by the targeted treatments. Read More |
TAYLORx | CCTG MAC12 featured in NEJM Notable Articles of 2018Published: February 06, 2019Category: Publications  The New England Journal of Medicine Notable Articles of 2018 recognizes the significance of the TAYLORx | CCTG MAC12 study, in addition, the Journal of Clinical Oncology has also named TAILORx as one of the most important clinical research advances of 2018. Read More |
|
|
January 23, 2019
 These CCTG trials have been formally permanently closed/terminated. No further ethics approvals or folow up data are required, more information can be found on the CCTG website under the "Toolbox". Read More |
 CCTG trials BL13 and IND237 have been centrally activated with further information please visit the trial pages. Read More |
 Trial-specific DSMC Summary Reports are now posted on trial websites. Single-study centres participating on these trials should download these reports and submit them to their Research Ethics Boards if required by local policy. Trials currently under CCTG's DSMC oversight include: Read More |